Projects per year
Abstract
Epilepsy is one of the most serious and common chronic neurological conditions, characterised by recurrent hypersynchronous electrical activity in the brain that lead to seizures. Despite over 50 million people being affected worldwide, only ~70% of people with epilepsy have their seizures successfully controlled with current pharmacotherapy, and many experience significant psychiatric and physical comorbidities. Adenosine, a ubiquitous purine metabolite, is a potent endogenous anti-epileptic substance that can abolish seizure activity via the adenosine A1 G protein-coupled receptor. Activation of A1 receptors decreases seizure activity in animal models, including models of drug-resistant epilepsy. Recent advances have increased our understanding of epilepsy comorbidities, highlighting the potential for adenosine receptors to modulate epilepsy-associated comorbidities, including cardiovascular dysfunction, sleep and cognition. This review provides an accessible resource of the current advances in understanding the adenosine system as a therapeutic target for epilepsy and epilepsy-associated comorbidities.
Original language | English |
---|---|
Pages (from-to) | 2143-2157 |
Number of pages | 15 |
Journal | British Journal of Pharmacology |
Volume | 181 |
Issue number | 14 |
DOIs | |
Publication status | Published - Jul 2024 |
Keywords
- adenosine
- cardiovascular disease
- cognition
- epilepsy
- G protein-coupled receptor
- SUDEP
-
Positive allosteric modulation of anti-convulsant G protein-coupled receptor signalling to treat drug-resistant epilepsy
May, L. (Primary Chief Investigator (PCI)), Webb, G. (Chief Investigator (CI)), Carlsson, J. (Chief Investigator (CI)), Baltos, J.-A. (Chief Investigator (CI)), TN Nguyen, A. (Chief Investigator (CI)), Christopoulos, A. (Associate Investigator (AI)), Miao, Y. (Associate Investigator (AI)), O'Brien, T. (Associate Investigator (AI)), Rollo, B. (Associate Investigator (AI)), Casillas-Espinosa, P. (Associate Investigator (AI)), Gregory, K. (Associate Investigator (AI)), Scammells, P. (Associate Investigator (AI)) & Nguyen, T. (Associate Investigator (AI))
1/01/22 → 31/12/25
Project: Research
-
ARC Industrial Transformation Training Centre for Cryo-Electron Microscopy of Membrane Proteins for Drug Discovery
Sexton, P. (Primary Chief Investigator (PCI)), Rouiller, I. (Chief Investigator (CI)), Wootten, D. (Chief Investigator (CI)), van Oijen, A. (Chief Investigator (CI)), Parker, M. W. (Chief Investigator (CI)), Lucet, I. (Partner Investigator (PI)), Griffin, M. D. W. (Chief Investigator (CI)), Adams, D. J. (Chief Investigator (CI)), Czabotar, P. E. (Partner Investigator (PI)), Flocco, M. (Partner Investigator (PI)), Han, S. (Partner Investigator (PI)), Shepherd, R. (Partner Investigator (PI)), Ciferri, C. (Partner Investigator (PI)), Williams, P. A. (Partner Investigator (PI)), Brown, D. (Partner Investigator (PI)), Schreuder, H. (Partner Investigator (PI)), Reedtz-Runge, S. (Partner Investigator (PI)), Drinkwater, C. (Partner Investigator (PI)), Howard, B. L. (Partner Investigator (PI)), Betigeri, G. (Partner Investigator (PI)), Pryor, E. (Partner Investigator (PI)), How, J. (Project Manager) & Christopoulos, T. (Chief Investigator (CI))
Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom)
23/03/21 → 23/03/27
Project: Research
-
Discovering new drugs for epilepsy using personalised medicine
Kwan, P. (Primary Chief Investigator (PCI)), Rollo, B. (Chief Investigator (CI)), Langmead, C. (Chief Investigator (CI)), Ayers, K. L. (Chief Investigator (CI)) & Harris, A. (Chief Investigator (CI))
1/06/20 → 31/05/22
Project: Research